ArticleHuman mutation2026
Epithelial Cell-Specific Prognostic Signature (FTH1, RIT1, WASL, NDRG2, KIFC3) Stratifies Cervical Cancer Patients and Correlates With Immune Infiltration.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer (CC) remains one of the leading female malignancies. Epithelial cells (EpCs), primarily derived from the cervical squamous and glandular epithelium, are targeted by human papillomavirus to drive CC. Herein, we aimed to develop an EpC-specific risk model to improve clinical outcomes and unravel tumor immune microenvironment alterations in CC. Methods: scRNA-seq data from GSE208653 were processed using Seurat (including SCTransform for normalization and Harmony for batch correction). EpC heterogeneity was analyzed via subclustering, pseudotime trajectory analysis with monocle2, and cell-cell communication inference with CellChat. The hdWGCNA package identified EpC-specific coexpression modules. Prognostic genes were screened by univariate Cox and LASSO regression, and a Riskscore model was built using multivariate Cox regression. Immune infiltration was assessed by ssGSEA, MCPCounter, and ESTIMATE algorithms. Drug sensitivity correlation was analyzed using pRRophetic. In vitro functional assays validated key gene roles in CC cells. Results: Forty thousand four hundred fifty-seven cells were annotated into eight cell populations with a lower percentage of EpCs. Thereafter, EpCs were categorized into three subclusters with specifically highly expressed genes in peculiar biological pathways and with distinct trajectories of fate. A strong cell-cell communication network was observed, particularly involving Ep C3 and immune cells, via ligand-receptor pairs such as LGALS9-CD44 and HBEGF-EGFR. The hdWGCNA analysis revealed Ep C3-specific gene modules, from which a five-gene prognostic signature ( Conclusion: A proposed EpC-specific gene signature for CC may be applicable to support clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.